CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Pharmaceuticals Partnered with Anthem Biosciences Pvt. Ltd. in Preparation for Upcoming Proposed Phase 2 Clinical Trial

Dec 17, 2019 8:00am EST

CNS' Berubicin Awarded $5.8 Million Non-Dilutive Grant from EU/Polish National Center Through its Development Partner

Dec 11, 2019 8:00am EST

CNS Pharmaceuticals Received Positive FDA Pre-IND Guidance for Berubicin

Dec 10, 2019 8:00am EST

CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event

Dec 09, 2019 8:00am EST

CNS Pharmaceuticals to Participate in 12th Annual LD Micro Main Event Conference

Dec 03, 2019 8:00am EST

CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals

Nov 26, 2019 8:00am EST

CNS Pharmaceuticals Announces Full Exercise of Over-Allotment Option

Nov 21, 2019 5:31pm EST

CNS Pharmaceuticals Filed Request with FDA for Pre-IND Meeting for Berubicin

Nov 21, 2019 8:00am EST

CNS Pharmaceuticals Announces Attendance at the 24th Annual Meeting of the Society of Neuro-Oncology

Nov 20, 2019 8:00am EST

CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals

Nov 19, 2019 8:00am EST
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    © 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

    • Brain
      • Glioblastoma
      • Anthracyclines
      • Blood Brain Barrier
    • Technology
      • Berubicin
      • Pipeline
    • Team
      • Management
      • Board
    • About Us
    • Contact
    • Investors
    • Sign Up